Ginkgo Bioworks Holdings Inc (DNA)

$0.9246

+0.05

(+6.08%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Ginkgo Bioworks Holdings Inc

  • Decreasing Revenue

    Revenue is down for the last 5 quarters, 98.28M → 34.75M (in $), with an average decrease of 21.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -302.89M → -211.69M (in $), with an average increase of 43.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 77.0%

Performance

  • $0.85
    $0.95
    $0.92
    downward going graph

    7.16%

    Downside

    Day's Volatility :10.37%

    Upside

    3.45%

    downward going graph
  • $0.85
    $2.55
    $0.92
    downward going graph

    7.61%

    Downside

    52 Weeks Volatility :66.67%

    Upside

    63.92%

    downward going graph

Returns

PeriodGinkgo Bioworks Holdings IncSector (Materials)Index (Russel 2000)
3 Months
-26.14%
8.3%
0.0%
6 Months
-47.18%
15.4%
0.0%
1 Year
-30.27%
8.9%
-1.5%
3 Years
-91.39%
7.7%
-21.8%

Highlights

Market Capitalization
2.0B
Book Value
$0.55
Earnings Per Share (EPS)
-0.46
Wall Street Target Price
1.97
Profit Margin
0.0%
Operating Margin TTM
-515.53%
Return On Assets TTM
-21.82%
Return On Equity TTM
-63.02%
Revenue TTM
251.5M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
-64.60000000000001%
Gross Profit TTM
273.5M
EBITDA
-662.3M
Diluted Eps TTM
-0.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.32
EPS Estimate Next Year
-0.27
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.08

Analyst Recommendation

Buy
    61%Buy
    23%Hold
    15%Sell
Based on 13 Wall street analysts offering stock ratings for Ginkgo Bioworks Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
3
3
3
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 113.07%

Current $0.92
Target $1.97

Company Financials

FY19Y/Y Change
Revenue
54.2M
-
Net Income
-119.9M
-
Net Profit Margin
-221.2%
-
FY20Y/Y Change
Revenue
76.7M
↑ 41.48%
Net Income
-126.7M
↑ 5.73%
Net Profit Margin
-165.31%
↑ 55.89%
FY21Y/Y Change
Revenue
313.8M
↑ 309.4%
Net Income
-1.8B
↑ 1349.34%
Net Profit Margin
-585.22%
↓ 419.91%
FY22Y/Y Change
Revenue
477.7M
↑ 52.21%
Net Income
-2.1B
↑ 14.69%
Net Profit Margin
-440.93%
↑ 144.29%
FY23Y/Y Change
Revenue
251.5M
↓ 47.36%
Net Income
-892.9M
↓ 57.61%
Net Profit Margin
-355.08%
↑ 85.85%
Q3 FY22Q/Q Change
Revenue
66.4M
↓ 54.09%
Net Income
-669.1M
↓ 0.23%
Net Profit Margin
-1.0K%
↓ 543.96%
Q4 FY22Q/Q Change
Revenue
98.3M
↑ 48.02%
Net Income
-174.2M
↓ 73.97%
Net Profit Margin
-177.19%
↑ 830.45%
Q1 FY23Q/Q Change
Revenue
80.7M
↓ 17.89%
Net Income
-205.0M
↑ 17.69%
Net Profit Margin
-253.98%
↓ 76.79%
Q2 FY23Q/Q Change
Revenue
80.6M
↓ 0.17%
Net Income
-173.3M
↓ 15.44%
Net Profit Margin
-215.12%
↑ 38.86%
Q3 FY23Q/Q Change
Revenue
55.4M
↓ 31.2%
Net Income
-302.9M
↑ 74.76%
Net Profit Margin
-546.44%
↓ 331.32%
Q4 FY23Q/Q Change
Revenue
34.8M
↓ 37.3%
Net Income
-211.7M
↓ 30.11%
Net Profit Margin
-609.1%
↓ 62.66%
FY19Y/Y Change
Total Assets
697.3M
-
Total Liabilities
195.5M
-
FY20Y/Y Change
Total Assets
675.2M
↓ 3.18%
Total Liabilities
205.1M
↑ 4.93%
FY21Y/Y Change
Total Assets
2.1B
↑ 206.74%
Total Liabilities
503.6M
↑ 145.54%
FY22Y/Y Change
Total Assets
2.5B
↑ 22.61%
Total Liabilities
803.0M
↑ 59.46%
FY23Y/Y Change
Total Assets
1.7B
↓ 34.42%
Total Liabilities
568.2M
↓ 29.25%
Q3 FY22Q/Q Change
Total Assets
1.9B
↓ 6.19%
Total Liabilities
431.0M
↑ 0.89%
Q4 FY22Q/Q Change
Total Assets
2.5B
↑ 35.74%
Total Liabilities
803.0M
↑ 86.34%
Q1 FY23Q/Q Change
Total Assets
2.4B
↓ 4.81%
Total Liabilities
809.6M
↑ 0.82%
Q2 FY23Q/Q Change
Total Assets
2.3B
↓ 5.18%
Total Liabilities
788.4M
↓ 2.62%
Q3 FY23Q/Q Change
Total Assets
2.0B
↓ 11.59%
Total Liabilities
773.7M
↓ 1.87%
Q4 FY23Q/Q Change
Total Assets
1.7B
↓ 17.82%
Total Liabilities
568.2M
↓ 26.56%
FY19Y/Y Change
Operating Cash Flow
-44.7M
-
Investing Cash Flow
-74.6M
-
Financing Cash Flow
410.4M
-
FY20Y/Y Change
Operating Cash Flow
-135.8M
↑ 204.12%
Investing Cash Flow
-67.1M
↓ 10.03%
Financing Cash Flow
90.3M
↓ 77.99%
FY21Y/Y Change
Operating Cash Flow
-253.8M
↑ 86.86%
Investing Cash Flow
-73.3M
↑ 9.14%
Financing Cash Flow
1.5B
↑ 1598.6%
FY22Y/Y Change
Operating Cash Flow
-252.2M
↓ 0.64%
Investing Cash Flow
-67.4M
↓ 8.0%
Financing Cash Flow
95.3M
↓ 93.79%
Q3 FY22Q/Q Change
Operating Cash Flow
572.6M
↓ 7.13%
Investing Cash Flow
-46.5M
↑ 217.03%
Financing Cash Flow
-450.0K
↓ 52.83%
Q4 FY22Q/Q Change
Operating Cash Flow
-104.7M
↓ 118.28%
Investing Cash Flow
-67.4M
↑ 44.98%
Financing Cash Flow
97.9M
↓ 21862.89%
Q1 FY23Q/Q Change
Operating Cash Flow
-90.6M
↓ 13.48%
Investing Cash Flow
-19.4M
↓ 71.19%
Financing Cash Flow
-888.0K
↓ 100.91%
Q2 FY23Q/Q Change
Operating Cash Flow
-73.5M
↓ 18.82%
Investing Cash Flow
-30.6M
↑ 57.81%
Financing Cash Flow
-1.4M
↑ 55.52%
Q3 FY23Q/Q Change
Operating Cash Flow
-73.6M
↑ 0.02%
Investing Cash Flow
-34.0M
↑ 11.04%
Financing Cash Flow
-315.0K
↓ 77.19%

Technicals Summary

Sell

Neutral

Buy

Ginkgo Bioworks Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks Holdings Inc
-20.04%
-47.18%
-30.27%
-91.39%
-91.39%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks Holdings Inc
NA
NA
NA
-0.32
-0.63
-0.22
NA
0.55
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks Holdings Inc
Buy
$2.0B
-91.39%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Baillie Gifford & Co Limited.

    10.98%

  • ARK Investment Management LLC

    9.23%

  • Viking Global Investors LP

    6.65%

  • Vanguard Group Inc

    6.17%

  • BlackRock Inc

    3.38%

  • Anchorage Advisors, LLC

    3.25%

Corporate Announcements

  • Ginkgo Bioworks Holdings Inc Earnings

    Ginkgo Bioworks Holdings Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.

Organization
Ginkgo Bioworks Holdings Inc
Employees
1218
CEO
Dr. Jason Kelly
Industry
Healthcare

Discover More

FAQs